Clinical Trial Details
| Trial ID: | L6496 |
| Source ID: | NCT00850161 |
| Associated Drug: | Aspart |
| Title: | Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin |
| Acronym: | |
| Status: | WITHDRAWN |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 1 Diabetes Mellitus |
| Interventions: | DRUG: aspart|DRUG: Nasulin™ |
| Outcome Measures: | Primary: The primary endpoint is to determine whether intranasal administration of Nasulin™ will stimulate glucose disposal and suppress endogenous glucose production., Blood will be measured at -30, -20, -10, 0, 2, 6, 8, 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 minutes | |
| Sponsor/Collaborators: | Sponsor: CPEX Pharmaceuticals Inc. |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE2 |
| Enrollment: | 0 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: BASIC_SCIENCE |
| Start Date: | 2009-07 |
| Completion Date: | 2010-09 |
| Results First Posted: | |
| Last Update Posted: | 2016-02-15 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00850161 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|